Status:
WITHDRAWN
Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China
Lead Sponsor:
Ipsen
Conditions:
Acromegaly
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the protocol is to achieve an in-depth understanding of the current satisfaction status of somatostatin analogue (SSA) treatment for acromegaly through patient and physician surveys.
Eligibility Criteria
Inclusion
- For Patients:
- Age 18 years or older
- Diagnosed with acromegaly
- Receiving current SSA injections for acromegaly treatment for at least 3 months
- Signed electronic Informed Consent Form (eICF)
- For Physicians:
- Licensed endocrinologists or neurosurgeons
- Having prescribed SSAs for at least five patients with acromegaly in the past 6 months
- Signed eICF
Exclusion
- Patients will not be included in the survey if they meet any of the following criteria:
- Patients who are not able to successfully complete the questionnaire independently
- Pregnant patients
Key Trial Info
Start Date :
February 13 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05184231
Start Date
February 13 2023
End Date
October 1 2023
Last Update
March 17 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.